Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.72 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.69 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.69 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.61 |
| ▸ | SELP | P16109 | 1/20 | 0.58 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.57 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.56 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14878462 | 1.00 | FABP3 (0.72) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL2734331 | 1.00 | FABP3 (0.72) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL30950728 | 1.00 | FABP3 (0.72) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL13638356 | 1.00 | FABP3 (0.72) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL14758291 | 0.95 | FABP3 (0.66) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL23188409 | 0.94 | SELP (0.68) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL23225813 | 0.94 | SELP (0.68) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL23188412 | 0.94 | SELP (0.68) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL15336893 | 0.94 | SELP (0.68) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL14887282 | 0.94 | SELP (0.68) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025056467-A1 | POLYPHOSPHOESTER STABILIZING AGENTS, COMPOSITIONS, USES, AND MANUFACTURING METHODS THEREOF | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC (CA) | 2025-03-20 | — | — | WO | claimed |
| WO-2025056466-A1 | POLYVINYLPYRROLIDONE STABILIZING AGENTS, COMPOSITIONS, USES, AND MANUFACTURING METHODS THEREOF | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC (CA) | 2025-03-20 | — | — | WO | claimed |
| WO-2025049579-A1 | INTRANASAL FORMULATION FOR PULMONARY DELIVERY OF NANOPARTICLES, COMPOSITIONS, USES, AND MANUFACTURING METHODS THEREOF | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC (CA) | 2025-03-06 | — | — | WO | claimed |
| CN-122055141-A | Polyvinylpyrrolidone stabilizer, composition, use and preparation method thereof | 环球生命科学解决方案加拿大有限公司 | 2026-05-15 | — | — | CN | disclosed |
| WO-2025056467-A1 | POLYPHOSPHOESTER STABILIZING AGENTS, COMPOSITIONS, USES, AND MANUFACTURING METHODS THEREOF | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC (CA) | 2025-03-20 | — | — | WO | disclosed |
| WO-2025056466-A1 | POLYVINYLPYRROLIDONE STABILIZING AGENTS, COMPOSITIONS, USES, AND MANUFACTURING METHODS THEREOF | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC (CA) | 2025-03-20 | — | — | WO | disclosed |
| WO-2025049579-A1 | INTRANASAL FORMULATION FOR PULMONARY DELIVERY OF NANOPARTICLES, COMPOSITIONS, USES, AND MANUFACTURING METHODS THEREOF | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC (CA) | 2025-03-06 | — | — | WO | disclosed |
| US-20170312375-A1 | PREPARATION OF A LIPID BLEND AND A PHOSPHOLIPID SUSPENSION CONTAINING THE LIPID BLEND | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-11-02 | — | — | US | disclosed |
| US-9545457-B2 | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20150023880-A1 | PREPARATION OF A LIPID BLEND AND A PHOSPHOLIPID SUSPENSION CONTAINING THE LIPID BLEND | LANTHEUS MEDICAL IMAGING, INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-8747892-B2 | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend | LANTHEUS MEDICAL IMAGING, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8658205-B2 | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend | LANTHEUS MEDICAL IMAGING, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-20130281510-A1 | siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis | KUMAMOTO UNIVERSITY (JP) | 2013-10-24 | — | — | US | disclosed |
| US-7906147-B2 | superparamagnetic nanoparticles of iron coated with bilayer of molecules:(a) layer of oleic acid in direct contact with the iron particles; (b) a layer of Tween\"; bilayer of surface binding molecules and amphiphatic molecules; self-assembles; solubilizing; reducing toxicity; gold in MRI and tomography | NANOPROBES, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20080089836-A1 | superparamagnetic nanoparticles of iron coated with bilayer of molecules:(a) layer of oleic acid in direct contact with the iron particles; (b) a layer of Tween\"; bilayer of surface binding molecules and amphiphatic molecules; self-assembles; solubilizing; reducing toxicity; gold in MRI and tomography | NANOPROBES, INC. (US) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170312375-A1 | PREPARATION OF A LIPID BLEND AND A PHOSPHOLIPID SUSPENSION CONTAINING THE LIPID BLEND | PHOSPHO1, PLTP, APOB | FABP3 21/4885LPAR3 40/4885LPAR1 43/4885 |
| US-20080089836-A1 | superparamagnetic nanoparticles of iron coated with bilayer of molecules:(a) layer of oleic acid in direct contact with the iron particles; (b) a layer of Tween\"; bilayer of surface binding molecules and amphiphatic molecules; self-assembles; solubilizing; reducing toxicity; gold in MRI and tomography | TFRC, FABP1, SCARB1 | FABP3 5/4885LPAR3 322/4885LPAR1 232/4885 |
| US-20150023880-A1 | PREPARATION OF A LIPID BLEND AND A PHOSPHOLIPID SUSPENSION CONTAINING THE LIPID BLEND | PHOSPHO1, PLTP, APOB | FABP3 21/4885LPAR3 40/4885LPAR1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.